欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 日本一级毛片在线播放 | 在线日本高清视频一区二区 | 色综合天天色综合久久网 | 中文字幕日本乱码仑区在线 | 国产精品无码2025在线观看 | 无码免费婬av片在线观看 | 欧洲一区二区 | 亚洲国产在一二区三区不卡 | 天干在线观看 | 成人午夜精品无码区久久中文 | 亚洲欧美精品综合中文字幕 | 国产精品亚洲一区二区久久 | 91九色露脸 | 欧美激情精品视频一区 | 日韩精品人妻av一区二区三区 | 成人小视频在 | 99久久人人爽亚洲精品美女 | 乱码伦视频免费 | 最新69国产精品视频 | 人妻精品久久久久中文字幕 | 国产日韩亚洲欧美av | 九九热在线观看官网 | 国产日韩精品九九久久 | 日韩看片无码免费网址 | 免费在线诱人的老师hd中文字 | 国产国产精品 | 色婷婷综合缴情综合免费观看 | 亚洲宅男精品一区在线观看 | 国产精品中的精品在线 | 亚洲成综合人在线播放 | 国产成成视频在线观看 | 亚洲热久久 | 成人亚洲欧美久久久久 | 日韩av在线亚洲 | 国产精品无码av无码 | 无码毛片一区二 | 99久久人妻无码精品系列蜜桃 | 亚洲成αv人片不卡无码播放 | 亚洲日韩精品无码av海量 | 午夜福利国产av | 综合色先锋资 |